The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups
Open accessAbstract
Purpose: To identify risk factors associated with outcome in children with metastatic rhabdomyosarcoma in a large cohort of patients Patients and Methods: Pooled data were obtained from 788 patients treated in nine studies performed by European and American cooperative groups. Clinical factors, including age, histology, site of primary, and site(s) and number of sites of metastatic disease, were correlated with event-free survival (EFS) and overall survival (OS). Results: Seven hundred eighty-eight patients were eligible for analysis. The 3-year OS and EFS were 34% (SE, 1.7) and 27% (SE, 1.6), respectively. By univariate analysis, 3-year EFS was significantly and adversely influenced by age, alveolar histology, location of primary tumor in unfavorable site (defined as extremity and “other” sites), presence of three or more sites of metastatic disease, and the presence of bone or bone marrow involvement. By multivariate analysis, EFS was strongly correlated to all factors except histology. Relative risks were 1.6 for age younger than 1 year or at least 10 years, 1.4 for unfavorable site of primary tumor, 1.4 for bone or bone marrow involvement, 1.4 for three or more metastatic sites. EFS was 50% for patients without any of these four adverse factors and was respectively 42%, 18%, 12%, and 5% in patients with one, two, three, or four factors (P < .0001). Conclusion: This analysis identified subsets of patients with metastatic rhabdomyosaroma with different outcomes to current therapy and offers a strategy to define patient candidates for experimental approaches to treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
The Third Intergroup Rhabdomyosarcoma Study.
Crist, W., Gehan, E. A., Ragab, A. H., Dickman, P. S., Donaldson, S. S., Fryer, C., Hammond, D., Hays, D. M., Herrmann, J., & Heyn, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.610 · Cited by 999
Breneman, J. C., Lyden, E., Pappo, A. S., Link, M. P., Anderson, J. R., Parham, D. M., Qualman, S. J., Wharam, M. D., Donaldson, S. S., Maurer, H. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.129 · Cited by 470
Self-citationStevens, M. C. G., Rey, A., Bouvet, N., Ellershaw, C., Flamant, F., Habrand, J. L., Marsden, H. B., Martelli, H., de Toledo, J. S., Spicer, R. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.130 · Cited by 339
Self-citationPetricoin, E. F., Espina, V., Araujo, R. P., Midura, B., Yeung, C., Wan, X., Eichler, G. S., Johann, D. J., Qualman, S., Tsokos, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1344 · Cited by 250
Joshi, D., Anderson, J. R., Paidas, C., Breneman, J., Parham, D. M., & Crist, W. (2004) · Pediatric Blood & Cancer · doi:10.1002/pbc.10441 · Cited by 232
Self-citationPappo, A. S., Lyden, E., Breitfeld, P., Donaldson, S. S., Wiener, E., Parham, D., Crews, K. R., Houghton, P., & Meyer, W. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1720 · Cited by 201
Self-citationCarli, M., Colombatti, R., Oberlin, O., Bisogno, G., Treuner, J., Koscielniak, E., Tridello, G., Garaventa, A., Pinkerton, R., & Stevens, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.083 · Cited by 176
Self-citationHigh-Dose Melphalan With Autologous Stem-Cell Rescue in Metastatic Rhabdomyosarcoma
Carli, M., Colombatti, R., Oberlin, O., Stevens, M. C. G., Masiero, L., Frascella, E., Kościelniak, E., Treuner, J., & Pinkerton, R. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2796 · Cited by 100
Self-citationBreitfeld, P. P., Lyden, E. R., Raney, R. B., Teot, L. A., Wharam, M. D., Lobe, T. E., Crist, W., Maurer, H. M., Donaldson, S. S., & Ruymann, F. B. (2001) · The American journal of pediatric hematology/oncology · doi:10.1097/00043426-200105000-00010 · Cited by 96
Self-citationExpression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma
Ganti, R., Skapek, S. X., Zhang, J., Fuller, C. E., Wu, J., Billups, C. A., Breitfeld, P. P., Dalton, J., Meyer, W. H., & Khoury, J. D. (2006) · Modern Pathology · doi:10.1038/modpathol.3800636 · Cited by 91
Self-citationGee, M. F. W., Tsuchida, R., Eichler-Jonsson, C., Das, B., Baruchel, S., & Malkin, D. M. (2005) · Oncogene · doi:10.1038/sj.onc.1208939 · Cited by 90
Koscielniak, E., Rodary, C., Flamant, F., Carli, M., Treuner, J., Pinkerton, C. R., & Grotto, P. (1992) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950200305 · Cited by 83
Self-citationWeigel, B. J., Breitfeld, P. P., Hawkins, D. S., Crist, W., & Baker, K. S. (2001) · The American journal of pediatric hematology/oncology · doi:10.1097/00043426-200106000-00007 · Cited by 69
Onisto, M., Slongo, M. L., Gregnanin, L., Gastaldi, T., Carli, M., & Rosolen, A. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.3.791 · Cited by 50
Self-citationFrascella, E., Pritchard‐Jones, K., Modak, S. I., Mancini, A., Carli, M., & Pinkerton, R. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00665-6 · Cited by 26
Self-citation(1993) · doi:10.1002/1097-0142(19930301)71:5<1904::aid-cncr2820710530>3.0.co;2-x
(1988) · doi:10.1002/1097-0142(19881001)62:7<1257::aid-cncr2820620703>3.0.co;2-k
(1988) · doi:10.1002/1097-0142(19880115)61:2<209::aid-cncr2820610202>3.0.co;2-l
Cited by
Outcomes for children and adolescents with cancer: challenges for the twenty-first century
Smith, M. A., Seibel, N. L., Altekruse, S. F., Ries, L. A. G., Melbert, D. L., O'Leary, M., Smith, F. O., & Reaman, G. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0421 · Cited by 1,026
“Children and adolescents with metastatic rhabdomyosarcoma and high-risk clinical features continue to have poor outcomes.(36) Germ cell tumors (non-CNS).”
BackgroundSkapek, S. X., Ferrari, A., Gupta, A. A., Lupo, P. J., Butler, E., Shipley, J., Barr, F. G., & Hawkins, D. S. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0051-2 · Cited by 875
Williamson, D., Missiaglia, E., de Reyniès, A., Pierron, G., Thuille, B., Palenzuela, G., Thway, K., Orbach, D., Laé, M., Fréneaux, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3814 · Cited by 502
Self-citationMalempati, S., & Hawkins, D. S. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24118 · Cited by 422
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
Mody, R. J., Wu, Y.-M., Lonigro, R. J., Cao, X., Roychowdhury, S., Vats, P., Frank, K. M., Prensner, J. R., Asangani, I., Palanisamy, N., et al. (2015) · JAMA · doi:10.1001/jama.2015.10080 · Cited by 411
Metadata
- Authors
- Oberlin, O., Rey, A., Lyden, E., Bisogno, G., Stevens, M. C. G., Meyer, W. H., Carli, M., & Anderson, J. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-05-10
- Volume
- 26
- Issue
- 14
- Pages
- 2384-2389
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2100034382
- Cited by
- 484
- References
- 23
- FWCI
- 12.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.